Deals In Depth: January 2016
Nestle Health signed a $1.9 billion microbiome deal with Seres; Thermo Fisher paid $1.3 billion for fellow life sciences company Affymetrix. Biopharma and device financing totaled $2.9 billion and $254 million, respectively.
You may also be interested in...
The January Nestlé Health-Seres alliance nets Seres one of the biggest up-front payments in several years for an ex-US product license, while Nestlé shows its continuing commitment to building a portfolio of GI nutritional therapeutics – an area where development efforts have been slow to take shape.
Improvements in generating, purifying, and delivering RNA material, as well as addressing challenges with degradation by enzymes, have made the RNA class more attractive to drug developers.
The market for new company creation in the biopharma sector remains healthy and poised to continue fostering the establishment of start-ups, based on a new In Vivo study of the strong initial investments that pharma and biotech companies receive.